Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 2/20 | 0.57 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.57 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.57 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.57 |
| ▸ | SRC | P12931 | 1/20 | 0.57 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.56 |
| ▸ | HSP90AB1 | P08238 | 3/20 | 0.56 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | TP53 | P04637 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | USP2 | O75604 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4446477 | 0.87 | P2RX7 (0.73) | FGFR1FGFR2FGFR4FGFR3SRC | |
| SCHEMBL12280399 | 0.85 | P2RX7 (0.69) | FGFR1FGFR2FGFR4FGFR3SRC | |
| SCHEMBL10068409 | 0.84 | P2RX7 (0.74) | FGFR1FGFR2FGFR4FGFR3SRC | |
| Bilawsone SCHEMBL3768549 | 0.80 | APAF1 (0.75) | HSP90AA1HSP90AB1P2RX7MAPTTP53 | |
| Bilawsone SCHEMBL30884954 | 0.80 | APAF1 (0.75) | HSP90AA1HSP90AB1P2RX7MAPTTP53 | |
| SCHEMBL3691126 | 0.79 | P2RX7 (0.56) | FGFR1FGFR2FGFR4FGFR3HSP90AA1 | |
| SCHEMBL27645881 | 0.78 | MAPT (0.86) | FGFR1FGFR2FGFR4FGFR3HSP90AA1 | |
| SCHEMBL14773924 | 0.77 | ME2 (0.74) | FGFR1FGFR2FGFR4FGFR3SRC | |
| SCHEMBL16745426 | 0.77 | APAF1 (0.58) | HSP90AA1HSP90AB1P2RX7MAPTTP53 | |
| SCHEMBL3927140 | 0.77 | P2RX7 (0.69) | HSP90AA1HSP90AB1P2RX7MAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030170865-A1 | Novel polypeptide of protein p140 and DNAs encoding it | ONO PHARMACEUTICAL CO., LTD. | 2003-09-11 | — | — | US | disclosed |
| EP-0659883-B1 | Protein p140 and DNA encoding it | ONO PHARMACEUTICAL CO (JP) | 2003-04-16 | — | — | EP | disclosed |
| US-6432913-B1 | ANTIDIABETIC AGENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-08-13 | — | — | US | disclosed |
| US-6303320-B1 | SCREENING FOR MODULATOR OF GLUCOSE USE; ADMINISTER MODULATOR TO CELLS IN VITRO, CULTURE CELLS, COMPARE PHOSPHORYLATED PROTEIN WITH GLUCOSE USE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2001-10-16 | — | — | US | disclosed |
| CN-1057096-C | A novel polypeptide of protein p140 and DNAS encoding it | ONO PHARMACEUTICAL CO (JP) | 2000-10-04 | — | — | CN | disclosed |
| US-5804411-A | KEY PROTEIN IN THE SIGNAL TRANSMISSION OF INSULIN; USEFUL IN THE PREVENTION AND/OR TREATMENT OF DIABETES | ONO PHARMACEUTICAL CO., LTD. (JP) | 1998-09-08 | — | — | US | disclosed |
| US-5506205-A | TREATMENT OF DIABETES | ONO PHARMACEUTICAL CO., LTD. (JP) | 1996-04-09 | — | — | US | disclosed |
| CN-1112127-A | A novel polypeptide of protein p140 and DNAS encoding it | ONO PHARMACEUTICAL CO (JP) | 1995-11-22 | — | — | CN | disclosed |
| EP-0659883-A2 | Protein p140 and DNA encoding it | ONO PHARMACEUTICAL CO., LTD. (JP) | 1995-06-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030170865-A1 | Novel polypeptide of protein p140 and DNAs encoding it | IAPP, FAM20C, GID4 | FGFR1 3874/4885FGFR2 4592/4885FGFR4 3815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.